Lipegfilgrastim
Top View
- Supplemental Material 1
- The Impact of Biosimilar Competition June 2016 the Impact of Biosimilar Competition Introduction
- The Impact of Biosimilar Competition in Europe Contents
- Lonquex, INN-Lipegfilgrastim
- Lonquex, INN-Lipegfilgrastim
- The Incidence and Clinical Features of Pegylated Filgrastim-Induced Acute
- Complications of Cancer Chemotherapy
- Fulphila, INN-Pegfilgrastim
- HEMATOPOIETIC AGENTS;GROWTH FACTORS,MINERALS and VITAMINS Phr.Volkan KAHRAMAN HGF’S
- Product Information for Auspar Lonquex Lipegfilgrastim (Rbe) Teva Pharma Australia Pty Ltd, PM- 2014-03142-1-4 Final 23 February 2016
- Lonquex, INN-Lipegfilgrastim
- Back Matter (PDF)
- Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care That Enables Cure
- Cost-Effectiveness and Budgetary Impact of Lipegfilgrastim for The
- Abstract Book
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Guideline for the Use of Granulocyte-Colony Stimulating Factor (G-CSF) in Adult Oncology and Haematology Patients
- (INN) for Biological and Biotechnological Substances